Sol-gel reports full-year 2023 financial results and corporate developments

An ongoing phase 3 clinical trial of sgt-610 for gorlin syndrome with the first patient screened; results are expected by the end of 2025 sol-gel maintains a cash runway into the second half of 2025 ness ziona, israel, march 13, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of sgt-610 (patidegib gel, 2%), an orphan drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in gorlin syndrome and partnered with galderma to commercialize two approved large-category dermatology products, twyneo® and epsolay®, in the u.s, today announced financial results for the full year ended december 31st, 2023 and provided a corporate update.
SLGL Ratings Summary
SLGL Quant Ranking